279 related articles for article (PubMed ID: 20658985)
1. Alzheimer's disease neurofibrillary degeneration: pivotal and multifactorial.
Iqbal K; Wang X; Blanchard J; Liu F; Gong CX; Grundke-Iqbal I
Biochem Soc Trans; 2010 Aug; 38(4):962-6. PubMed ID: 20658985
[TBL] [Abstract][Full Text] [Related]
2. Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention.
Iqbal K; Grundke-Iqbal I
J Cell Mol Med; 2008; 12(1):38-55. PubMed ID: 18194444
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of tau-induced neurodegeneration.
Iqbal K; Liu F; Gong CX; Alonso Adel C; Grundke-Iqbal I
Acta Neuropathol; 2009 Jul; 118(1):53-69. PubMed ID: 19184068
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles.
Iqbal K; Alonso AC; Gong CX; Khatoon S; Pei JJ; Wang JZ; Grundke-Iqbal I
J Neural Transm Suppl; 1998; 53():169-80. PubMed ID: 9700655
[TBL] [Abstract][Full Text] [Related]
5. AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies.
Vingtdeux V; Davies P; Dickson DW; Marambaud P
Acta Neuropathol; 2011 Mar; 121(3):337-49. PubMed ID: 20957377
[TBL] [Abstract][Full Text] [Related]
6. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration.
Wang JZ; Xia YY; Grundke-Iqbal I; Iqbal K
J Alzheimers Dis; 2013; 33 Suppl 1():S123-39. PubMed ID: 22710920
[TBL] [Abstract][Full Text] [Related]
7. Significance and mechanism of Alzheimer neurofibrillary degeneration and therapeutic targets to inhibit this lesion.
Iqbal K; Alonso Adel C; El-Akkad E; Gong CX; Haque N; Khatoon S; Pei JJ; Tsujio I; Wang JZ; Grundke-Iqbal I
J Mol Neurosci; 2002; 19(1-2):95-9. PubMed ID: 12212801
[TBL] [Abstract][Full Text] [Related]
8. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.
Wang JZ; Grundke-Iqbal I; Iqbal K
Eur J Neurosci; 2007 Jan; 25(1):59-68. PubMed ID: 17241267
[TBL] [Abstract][Full Text] [Related]
9. Tau pathology in Alzheimer disease and other tauopathies.
Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I
Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638
[TBL] [Abstract][Full Text] [Related]
10. A NH2 tau fragment targets neuronal mitochondria at AD synapses: possible implications for neurodegeneration.
Amadoro G; Corsetti V; Stringaro A; Colone M; D'Aguanno S; Meli G; Ciotti M; Sancesario G; Cattaneo A; Bussani R; Mercanti D; Calissano P
J Alzheimers Dis; 2010; 21(2):445-70. PubMed ID: 20571215
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Protein Phosphatase-2A (PP2A) by I1PP2A Leads to Hyperphosphorylation of Tau, Neurodegeneration, and Cognitive Impairment in Rats.
Wang X; Blanchard J; Tung YC; Grundke-Iqbal I; Iqbal K
J Alzheimers Dis; 2015; 45(2):423-35. PubMed ID: 25589718
[TBL] [Abstract][Full Text] [Related]
12. Tau truncation is a productive posttranslational modification of neurofibrillary degeneration in Alzheimer's disease.
Kovacech B; Novak M
Curr Alzheimer Res; 2010 Dec; 7(8):708-16. PubMed ID: 20678071
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of neurofibrillary degeneration: a promising approach to Alzheimer's disease and other tauopathies.
Iqbal K; Grundke-Iqbal I
Curr Drug Targets; 2004 Aug; 5(6):495-502. PubMed ID: 15270196
[TBL] [Abstract][Full Text] [Related]
14. Role of microtubule-associated protein tau phosphorylation in Alzheimer's disease.
Ma RH; Zhang Y; Hong XY; Zhang JF; Wang JZ; Liu GP
J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):307-312. PubMed ID: 28585125
[TBL] [Abstract][Full Text] [Related]
15. Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease.
Iqbal K; Gong CX; Liu F
Expert Opin Ther Targets; 2014 Mar; 18(3):307-18. PubMed ID: 24387228
[TBL] [Abstract][Full Text] [Related]
16. Tau mediated neurodegeneration: an insight into Alzheimer's disease pathology.
Obulesu M; Venu R; Somashekhar R
Neurochem Res; 2011 Aug; 36(8):1329-35. PubMed ID: 21509508
[TBL] [Abstract][Full Text] [Related]
17. Impaired brain glucose metabolism leads to Alzheimer neurofibrillary degeneration through a decrease in tau O-GlcNAcylation.
Gong CX; Liu F; Grundke-Iqbal I; Iqbal K
J Alzheimers Dis; 2006 Mar; 9(1):1-12. PubMed ID: 16627930
[TBL] [Abstract][Full Text] [Related]
18. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease.
Streit WJ; Braak H; Xue QS; Bechmann I
Acta Neuropathol; 2009 Oct; 118(4):475-85. PubMed ID: 19513731
[TBL] [Abstract][Full Text] [Related]
19. The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment.
Wang X; Blanchard J; Kohlbrenner E; Clement N; Linden RM; Radu A; Grundke-Iqbal I; Iqbal K
FASEB J; 2010 Nov; 24(11):4420-32. PubMed ID: 20651003
[TBL] [Abstract][Full Text] [Related]
20. Insulin deprivation induces PP2A inhibition and tau hyperphosphorylation in hTau mice, a model of Alzheimer's disease-like tau pathology.
Gratuze M; Julien J; Petry FR; Morin F; Planel E
Sci Rep; 2017 Apr; 7():46359. PubMed ID: 28402338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
